RA0277

antibody from Oursmab

Targeting: GPC3 DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0277

Provider

Oursmab

Product name

Codrituzumab (Biosimilar Reference Antibody) (GPC3)

Antibody type

Monoclonal

Description

Codrituzumab (also known as GC33 or RG-7597) is an investigational humanized monoclonal antibody that was developed as a targeted therapy for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It was designed to bind specifically to an antigen that is highly expressed on the surface of HCC tumor cells but largely absent from healthy liver tissue. Despite a strong preclinical rationale, the drug¡¯s clinical development in later-stage trials did not demonstrate a significant survival benefit over existing standard of care, and its development appears to have been discontinued.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Codrituzumab (Biosimilar Reference Antibody) (GPC3)-RA0277-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Codrituzumab (Biosimilar Reference Antibody) (GPC3)-RA0277 in a linear range of 3.91-125 ng/mL.